Current Landscape and Open Questions on Adjuvant Therapies in Melanoma
Keywords:
stage III melanoma, adjuvant therapy, locoregional melanomaAbstract
Melanoma is a form of skin cancer that is frequently diagnosed at early stages. In most cases, surgical resection is curative. In case of thicker melanomas (> pT1b) without clinical or instrumental evidence of metastasis, a sentinel lymph node biopsy is recommended for staging purposes. If the lymph nodes are the only site of disease (macroscopic or microscopic> 1mm), configuring stage III, the international guidelines recommend the use of adjuvant therapy with checkpoint inhibitors (nivolumab or pembrolizumab) or targeted therapies (dabrafenib plus trametinib). These drugs have shown a significant increase in recurrence-free survival, although some doubts and open questions remain. Specifically, none of the available treatments has shown a clear benefit in the overall survival rates, the advantages they give in stage IIIA are not well known, and finally there are still no prospective clinical studies identifying the best approach to continue the therapeutic process in case of relapse. Furthermore, there are new opportunities opening up with the upcoming results of the neoadjuvant trials that could revolutionize the treatment of clinically evident stage III melanoma.
References
Paulson KG, Gupta D, Kim TS, et al. Age-Specific Incidence of Melanoma in the United States. JAMA Dermatol. 2020;156(1):57-64. DOI:10.1001/jamadermatol.2019.3353. PMID:31721989.
Giunta EF, De Falco V, Napolitano S, et al. Optimal treatment strategy for metastatic melanoma patients harboring BRAF-V600 mutations. Ther Adv Med Oncol. 2020;12. DOI:10.1177/1758835920925219. PMID: 32612709.
Balch CM, Gershenwald JE, Soong S-J, et al. Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol. 2009;27(36):6199-6206. DOI:10.1200/JCO.2009.23.4799. PMID: 19917835.
Ives NJ, Suciu S, Eggermont AMM, et al. Adjuvant interferon-α for the treatment of high-risk melanoma: An individual patient data meta-analysis. Eur J Cancer. 2017;82:171-183. DOI:10.1016/j.ejca.2017.06.006. PMID: 28692949.
Michielin O, van Akkooi ACJ, Ascierto PA, Dummer R, Keilholz U, ESMO Guidelines Committee. Electronic address: clinicalguidelines@esmo.org. Cutaneous melanoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†. Ann Oncol. 2019;30(12):1884-1901. DOI:10.1093/annonc/mdz411. PMID: 31566661.
Eggermont AMM, Chiarion-Sileni V, Grob J-J, et al. Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy. New England Journal of Medicine. 2016;375(19):1845-1855. DOI:10.1056/NEJMoa1611299. PMID: 27717298.
Weber J, Mandala M, Del Vecchio M, et al. Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma. New England Journal of Medicine. 2017;377(19):1824-1835. doi:10.1056/NEJMoa1709030. PMID: 28891423.
Ascierto PA, Del Vecchio M, Mandalá M, et al. Adjuvant nivolumab versus ipilimumab in resected stage IIIB-C and stage IV melanoma (CheckMate 238): 4-year results from a multicentre, double-blind, randomised, controlled, phase 3 trial. Lancet Oncol. 2020;21(11):1465-1477. DOI:10.1016/S1470-2045(20)30494-0.
Eggermont AMM, Blank CU, Mandala M, et al. Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma. New England Journal of Medicine. 2018;378(19):1789-1801. DOI:10.1056/NEJMoa1802357. PMID: 29658430.
Grossmann KF, Othus M, Patel SP, et al. Final analysis of overall survival (OS) and relapse-free-survival (RFS) in the intergroup S1404 phase III randomized trial comparing either high-dose interferon (HDI) or ipilimumab to pembrolizumab in patients with high-risk resected melanoma. JCO. 2021;39(15_suppl):9501-9501. DOI:10.1200/JCO.2021.39.15_suppl.9501.
Zimmer L, Livingstone E, Hassel JC, et al. Adjuvant nivolumab plus ipilimumab or nivolumab monotherapy versus placebo in patients with resected stage IV melanoma with no evidence of disease (IMMUNED): a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet. 2020;395(10236):1558-1568. DOI:10.1016/S0140-6736(20)30417-7.
Long GV, Schadendorf D, Vecchio MD, et al. Abstract CT004: Adjuvant therapy with nivolumab (NIVO) combined with ipilimumab (IPI) vs NIVO alone in patients (pts) with resected stage IIIB-D/IV melanoma (CheckMate 915). Cancer Res. 2021;81(13 Supplement):CT004-CT004. DOI:10.1158/1538-7445.AM2021-CT004.
Long GV, Hauschild A, Santinami M, et al. Adjuvant Dabrafenib plus Trametinib in Stage III BRAF-Mutated Melanoma. New England Journal of Medicine. 2017;377(19):1813-1823. DOI:10.1056/NEJMoa1708539. PMID:28891408.
Faries MB, Thompson JF, Cochran AJ, et al. Completion Dissection or Observation for Sentinel-Node Metastasis in Melanoma. N Engl J Med. 2017;376(23):2211-2222. DOI:10.1056/NEJMoa1613210. PMID: 28591523.
Leiter U, Stadler R, Mauch C, et al. Final Analysis of DeCOG-SLT Trial: No Survival Benefit for Complete Lymph Node Dissection in Patients With Melanoma With Positive Sentinel Node. J Clin Oncol. 2019;37(32):3000-3008. DOI:10.1200/JCO.18.02306. PMID: 31557067.
Gershenwald JE, Scolyer RA, Hess KR, et al. Melanoma staging: Evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manual. CA: A Cancer Journal for Clinicians. 2017;67(6):472-492. DOI:10.3322/caac.21409. PMID: 29028110.
Garbe C, Keim U, Suciu S, et al. Prognosis of Patients With Stage III Melanoma According to American Joint Committee on Cancer Version 8: A Reassessment on the Basis of 3 Independent Stage III Melanoma Cohorts. J Clin Oncol. 2020;38(22):2543-2551. DOI:10.1200/JCO.19.03034. PMID: 32530760.
Michielin O, van Akkooi A, Lorigan P, et al. ESMO consensus conference recommendations on the management of locoregional melanoma: under the auspices of the ESMO Guidelines Committee. Ann Oncol. 2020;31(11):1449-1461. DOI:10.1016/j.annonc.2020.07.005. PMID: 32763452.
Owen CN, Shoushtari AN, Chauhan D, et al. Management of early melanoma recurrence despite adjuvant anti-PD-1 antibody therapy☆. Ann Oncol. 2020;31(8):1075-1082. DOI:10.1016/j.annonc.2020.04.471. PMID: 32387454.
Bhave P, Pallan L, Atkinson V, et al. Melanoma recurrence after adjuvant targeted therapy: A multicenter analysis. JCO. 2020;38(15_suppl):10016-10016. DOI:10.1200/JCO.2020.38.15_suppl.10016.
Bhave P, Pallan L, Long GV, et al. Melanoma recurrence patterns and management after adjuvant targeted therapy: a multicentre analysis. British Journal of Cancer. 2021;124(3):574-580. DOI:10.1038/s41416-020-01121-y. PMID: 33087895.
Crossover and rechallenge with pembrolizumab in recurrent patients from the EORTC 1325-MG/Keynote-054 phase 3 trial, pembrolizumab versus placebo after complete resection of high-risk stage III melanoma. Journal of Clinical Oncology. Accessed July 13, 2021. https://ascopubs.org/doi/abs/10.1200/JCO.2021.39.15_suppl.9500
Menzies AM, Amaria RN, Rozeman EA, et al. Pathological response and survival with neoadjuvant therapy in melanoma: a pooled analysis from the International Neoadjuvant Melanoma Consortium (INMC). Nature Medicine. 2021;27(2):301-309. DOI:10.1038/s41591-020-01188-3. PMID: 33558722.
Published
Issue
Section
License
Dermatology Practical & Conceptual applies a Creative Commons Attribution License (CCAL) to all works we publish (http://creativecommons.org/licenses/by-nc/4.0/). Authors retain the copyright for their published work.
How to Cite
Share
